# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-25-110824
Filing Date
2025-11-13
Accepted
2025-11-13 06:58:56
Documents
60
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | plx-20250930x10q.htm iXBRL | 10-Q | 1152402
2 | EX-10.1 | plx-20250930xex10d1.htm | EX-10.1 | 853206
3 | EX-31.1 | plx-20250930xex31d1.htm | EX-31.1 | 12468
4 | EX-31.2 | plx-20250930xex31d2.htm | EX-31.2 | 12642
5 | EX-32.1 | plx-20250930xex32d1.htm | EX-32.1 | 6713
6 | EX-32.2 | plx-20250930xex32d2.htm | EX-32.2 | 6741
7 | GRAPHIC | plx-20250930x10q005.jpg | GRAPHIC | 71042
8 | GRAPHIC | plx-20250930x10q006.jpg | GRAPHIC | 38391
9 | GRAPHIC | plx-20250930x10q007.jpg | GRAPHIC | 56626
10 | GRAPHIC | plx-20250930x10q008.jpg | GRAPHIC | 40218
| Complete submission text file | 0001104659-25-110824.txt |  | 6493059

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
11 | EX-101.SCH | plx-20250930.xsd | EX-101.SCH | 35037
12 | EX-101.CAL | plx-20250930_cal.xml | EX-101.CAL | 51594
13 | EX-101.DEF | plx-20250930_def.xml | EX-101.DEF | 122019
14 | EX-101.LAB | plx-20250930_lab.xml | EX-101.LAB | 270017
15 | EX-101.PRE | plx-20250930_pre.xml | EX-101.PRE | 211859
63 | EXTRACTED XBRL INSTANCE DOCUMENT | plx-20250930x10q_htm.xml | XML | 759954

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 251475310
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)